New Method of Protein Ligation Developed
Credit: Shixian Lin/Berkeley Lab
Chemists have developed a powerful new method of selectively linking chemicals to proteins, a major advance in the manipulation of bio-molecules that could transform the way drugs are developed, proteins are probed, and molecules are tracked and imaged. The new technique, called redox activated chemical tagging (ReACT), is described in the Feb. 10 issue of the journal Science. Developed at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab), it could fundamentally change the process of bio-conjugation, the process by which chemicals and tags are attached to bio-molecules, particularly proteins.
“We’ve essentially invented a new type of chemical Swiss army knife for proteins, the first that can be used for the essential and naturally occurring amino acid methionine,” said study principal investigator Christopher Chang. “This ReACT method can be incorporated into a variety of different tools depending on what you need it to do. You can mix-and-match different reagents for a variety of applications.”
Chang and fellow Berkeley Lab faculty scientist F. Dean Toste led this work as part of the Catalysis Program at Berkeley Lab’s Chemical Sciences Division. Chang is also a Howard Hughes Medical Institute Investigator. Toste compared the process of bio-conjugation to hitching cargo onto the back of a pickup truck.
“That cargo can be used for many purposes,” he said. “It can deliver drugs to cancerous cells, or it can be used as a tracking device to monitor the truck’s movements. We can even modify the truck and change it to an ambulance. This change can be done in a number of ways, like rebuilding a truck or putting on a new hitch.”
Bio-conjugation traditionally relies upon the amino acid cysteine, which is highly reactive. Cysteine is often used as an attachment point for tags and chemical groups because it is one of two amino acids that contain sulphur, providing an anchor for acid-base chemistry and making it easy to modify. However, cysteine is often involved in the actual function of proteins, so “hitching cargo” to it creates instability and disrupts its natural function.
For this reason, people have been looking for ways to circumvent cysteine, and they naturally turned to methionine, the only other sulphur amino acid available. However, methionine has an extra carbon atom attached to its sulphur, which blocks most hitches. The researchers developed a new hitch using a process called oxidation-reduction chemistry that allows cargo to be attached to the methionine sulphur with this extra carbon still attached.
A key benefit to methionine is that it is a relatively rare amino acid, which allows researchers to selectively target it with fewer side effects and less impact on the bio-molecule. They put ReACT to the test by synthesizing an antibody-drug conjugate to highlight its applicability to biological therapeutics. They also identified the metabolic enzyme enolase as a potential therapeutic target for cancer, showing that the tool could help home in on new targets for drug discovery.
In the long term, the researchers say, this new bio-conjugation tool could be used in:
- Nanotechnology, where protein conjugation can help make nanomaterials compatible with air and water, reducing toxicity.
- The creation of artificial enzymes that can be recycled, have better stability, and have improved activity and selectivity through chemical protein modification.
- Synthetic biology, where it can be used to selectively make new proteins or augment the function of existing ones.
“This method could also add to the functionality of living organisms by directly modifying natural proteins to improve their stability and activity without making a genetically modified organism that relies on gene editing,” said Chang. “It could have implications for the sustainable production of fuels, food, or medicines, as well as in bio-remediation.”
This article has been republished from materials provided by Berkeley Lab. Note: material may have been edited for length and content. For further information, please contact the cited source.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE